Navigation Links
Immtech Announces Results From Hepatitis C Discovery Program
Date:6/3/2008

NEW YORK, June 3 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today positive results against the hepatitis C virus (HCV) of a compound from its drug discovery portfolio. The prototype compound belongs to an expanding class of compounds that has previously demonstrated activity against a related surrogate virus, bovine viral diarrhea virus (BVDV). The compound was found to have significant activity against HCV under assay conditions designed to demonstrate inhibition of the virus entry process, using a newly available in vitro cell culture system that employs infectious and replicating virus.

Norman Abood, Ph.D., Sr. Vice President, Discovery Programs, stated, "We aim to develop a compound with a novel mechanism of action that is complementary to the currently recognized treatments of HCV. It appears that Immtech's class of compounds inhibits an early, non-replicative step in the virus life cycle, based upon our earlier work in BVDV. The majority of the industry's efforts have focused on programs to identify drug candidates, such as protease and polymerase inhibitors, which inhibit HCV virus replication. Our latest findings provide an approach that will allow us to potentially identify a drug candidate with a new and complementary mechanism of action."

As of 2005 there were more than 11 million people living with hepatitis C in major markets around the world, and the sale of drugs to treat the disease, including treatments that are prescribed after a first course of treatment fails, was $3 billion. The HCV drug market is expected to expand to $9 billion in 2012 and to more than $10 billion annually by 2014.

About Immtech Pharmaceuticals, Inc.

Immtech is a pharmaceutical company focused on the development and commercialization of new drugs to treat infectious diseases. Immtech has a well defined, expanding library of compounds targeting Hepatitis C, drug-resistant Gram-positive bacteria, fungal infections and other serious diseases. It is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat a range of disorders. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit the Company's website at http://www.immtechpharma.com

This press release contains "forward-looking statements" regarding Immtech Pharmaceuticals, Inc.'s business. Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) potential exposure to significant product liability.

Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Completes Malaria Prevention Trial
2. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
3. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
4. Immtech Investor Conference Call Scheduled for February 22, 2008
5. Immtech Announces Update on Business Operations
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 19, 2017 , ... HealthSmart, the largest ... James (Jim) Vertino as Chief Information Officer (CIO). He will be joining HealthSmart ... innovation and business performance. He defines strategic roadmaps by reimagining business processes—bridging the ...
(Date:5/21/2017)... , ... May 21, 2017 , ... Florida Pain Relief ... opening of its newest location at 109 Silver Palm Ave., Melbourne, on Monday, May ... , With the opening of the Melbourne practice, PPOA operates 23 pain management clinics ...
(Date:5/19/2017)... ... 19, 2017 , ... A leader in higher education and ... recruitment efforts for the inaugural cohort of its online Master of Health ... to approach and address the unique nuances healthcare organizations face using a business-minded ...
(Date:5/19/2017)... ... May 19, 2017 , ... The ... planning assistance to families and business owners in the region, is embarking on ... MS sufferers and their families. , Multiple sclerosis (MS) is a demyelinating disease ...
(Date:5/19/2017)... Scottsdale, AZ (PRWEB) , ... May 18, 2017 , ... ... are known for being non-irritating while extremely helpful for mouth and gum health, which ... first introduced their professionals and customers learned quickly of the powerful ways in which ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... is Stroke Awareness Month and Omron Healthcare is reminding ... prevent a stroke: monitor and manage your blood pressure. ... undetected and uncontrolled hypertension is a leading risk factor ... personal heart health technology, recently evolved its mission to ... and is advancing a national public education effort to ...
(Date:5/4/2017)... , May 4, 2017 Clarius Mobile ... wireless, handheld ultrasound scanners this week at the ... Meeting (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians ... heart rate, and evaluate pregnancy-related complications like ectopic ...
(Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
Breaking Medicine Technology: